NO20065201L - terapeutiske peptider - Google Patents
terapeutiske peptiderInfo
- Publication number
- NO20065201L NO20065201L NO20065201A NO20065201A NO20065201L NO 20065201 L NO20065201 L NO 20065201L NO 20065201 A NO20065201 A NO 20065201A NO 20065201 A NO20065201 A NO 20065201A NO 20065201 L NO20065201 L NO 20065201L
- Authority
- NO
- Norway
- Prior art keywords
- ligand
- present
- provides
- therapeutic peptides
- product
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
- C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0408390A GB0408390D0 (en) | 2004-04-15 | 2004-04-15 | Therapeutic peptides |
GB0419594A GB0419594D0 (en) | 2004-09-03 | 2004-09-03 | Therapeutic peptides |
PCT/GB2005/001465 WO2005099337A2 (en) | 2004-04-15 | 2005-04-15 | Therapeutic peptides |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20065201L true NO20065201L (no) | 2006-11-13 |
Family
ID=35033424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20065201A NO20065201L (no) | 2004-04-15 | 2006-11-13 | terapeutiske peptider |
Country Status (11)
Country | Link |
---|---|
EP (2) | EP2468863A1 (ko) |
JP (2) | JP4960219B2 (ko) |
KR (1) | KR20070001274A (ko) |
AU (1) | AU2005232437B2 (ko) |
BR (1) | BRPI0509936A (ko) |
CA (1) | CA2563332A1 (ko) |
IL (1) | IL178517A0 (ko) |
MX (1) | MXPA06011501A (ko) |
NO (1) | NO20065201L (ko) |
NZ (1) | NZ551204A (ko) |
WO (1) | WO2005099337A2 (ko) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008029271A2 (en) | 2006-02-27 | 2008-03-13 | Gal Markel | Ceacam based antibacterial agents |
EP2042187A1 (en) * | 2007-09-27 | 2009-04-01 | Charité-Universitätsmedizin Berlin (Charité) | Use of soluble CEACAM8 for diagnosing, treating or monitoring diseases, and a method for screening compounds that prevent apoptosis |
US20170044268A1 (en) * | 2013-12-23 | 2017-02-16 | OncoMed Pharmaceuticals | Immunotherapy with Binding Agents |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9714160A (pt) * | 1996-12-20 | 2000-05-02 | Univ Texas | Antìgenos uspa1 e uspa2 de moraxella catarrhalis |
GB0222764D0 (en) * | 2002-10-02 | 2002-11-06 | Univ Bristol | Therapeutic peptide |
-
2005
- 2005-04-15 AU AU2005232437A patent/AU2005232437B2/en not_active Ceased
- 2005-04-15 WO PCT/GB2005/001465 patent/WO2005099337A2/en active Application Filing
- 2005-04-15 MX MXPA06011501A patent/MXPA06011501A/es unknown
- 2005-04-15 CA CA002563332A patent/CA2563332A1/en not_active Abandoned
- 2005-04-15 BR BRPI0509936-6A patent/BRPI0509936A/pt not_active IP Right Cessation
- 2005-04-15 JP JP2007507850A patent/JP4960219B2/ja not_active Expired - Fee Related
- 2005-04-15 EP EP11170229A patent/EP2468863A1/en not_active Withdrawn
- 2005-04-15 EP EP05735984A patent/EP1735446A2/en not_active Withdrawn
- 2005-04-15 NZ NZ551204A patent/NZ551204A/en not_active IP Right Cessation
- 2005-04-15 KR KR1020067023963A patent/KR20070001274A/ko not_active Application Discontinuation
-
2006
- 2006-10-05 IL IL178517A patent/IL178517A0/en unknown
- 2006-11-13 NO NO20065201A patent/NO20065201L/no not_active Application Discontinuation
-
2011
- 2011-12-09 JP JP2011270450A patent/JP2012097099A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
AU2005232437A1 (en) | 2005-10-27 |
JP4960219B2 (ja) | 2012-06-27 |
EP1735446A2 (en) | 2006-12-27 |
WO2005099337A3 (en) | 2006-08-10 |
EP2468863A1 (en) | 2012-06-27 |
IL178517A0 (en) | 2007-02-11 |
NZ551204A (en) | 2010-03-26 |
MXPA06011501A (es) | 2007-01-26 |
JP2012097099A (ja) | 2012-05-24 |
JP2007532618A (ja) | 2007-11-15 |
AU2005232437B2 (en) | 2011-10-06 |
CA2563332A1 (en) | 2005-10-27 |
KR20070001274A (ko) | 2007-01-03 |
WO2005099337A2 (en) | 2005-10-27 |
BRPI0509936A (pt) | 2007-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Angeletti et al. | Understanding and manipulating viral immunity: antibody immunodominance enters center stage | |
Davies et al. | Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice | |
BR112019018307A2 (pt) | Plataforma para identificação de peptídeos imunogênicos baseada em população | |
Prasad et al. | Presentation of cryptic peptides by MHC class I is enhanced by inflammatory stimuli | |
Mihailidou et al. | CHOP-dependent regulation of p21/waf1 during ER stress | |
CA2678404C (en) | Brachyury polypeptides and methods for use | |
RU2017105515A (ru) | Сигнальная система | |
KR20230076867A (ko) | 신생항원 백신과의 병용 요법 | |
Choi et al. | Chimeric hemagglutinin-based influenza virus vaccines induce protective stalk-specific humoral immunity and cellular responses in mice | |
BR112022018088A2 (pt) | Novos anticorpos anti-lilrb4 e produtos derivados | |
Tani et al. | Quantification by LC–MSE of outer membrane vesicle proteins of the Bexsero® vaccine | |
Maeda et al. | Adjuvant-mediated epitope specificity and enhanced neutralizing activity of antibodies targeting dengue virus envelope protein | |
Ménoret et al. | Differential proteomics identifies PDIA3 as a novel chemoprevention target in human colon cancer cells | |
NO20065201L (no) | terapeutiske peptider | |
WO2011160174A1 (en) | Treatment of proliferative diseases | |
Vanhove et al. | XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2 spike receptor-binding domain, targets multiple epitopes and broadly neutralizes variants | |
NO20052108L (no) | Terapeutiske peptider. | |
BRPI0516933B8 (pt) | métodos para o isolamento da haptoglobina humana, das isoformas de hp humana individuais, e da albumina e da haptoglobina humana | |
Bian et al. | Characterization of immunogenicity of malignant cells with stemness in intrahepatic cholangiocarcinoma by single‐cell RNA sequencing | |
WO2006046134A3 (en) | Method of screening by using conformation sensitive peptides | |
De Silva et al. | The hevein domain of the major latex‐glove allergen Hev b 6.01 contains dominant T cell reactive sites | |
Kuehnle et al. | CRISPR screens identify novel regulators of cFLIP dependency and ligand-independent, TRAIL-R1-mediated cell death | |
US11690902B2 (en) | Coxiella burnetii epitopes for T cell-targeted Q fever vaccines | |
WO2022131832A1 (ko) | 신규 코로나바이러스 예방 및 치료용 백신 조성물 | |
WO2015025165A1 (en) | T cell epitopes of classical swine fever virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |